AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment of amyotrophic lateral sclerosis (ALS) in Canada under the NOC/c procedure and to provide an update on its clinical program in all indications.
PRESS RELEASE
AB SCIENCE WILL HOST A LIVE WEBCAST ON MONDAY FEBRUARY 28, 2022TO PROVIDE DETAILS ON THE MASITINIB FILING IN THE TREATMENT OF ALS IN CANADA AND TO PROVIDE UPDATE ON ITS CLINICAL PROGRAM IN ALL INDICATIONS
Paris, February 24, 2022, 6pm CET
AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment of amyotrophic lateral sclerosis (ALS) in Canada under the NOC/c procedure and to provide an update on its clinical program in all indications.
The following attendees will participate to the webcast:
- Alain Moussy, co-founder and CEO of AB Science
- Laurent Guy, CFO of AB Science
- Olivier Hermine, president of AB Science scientific committee and member of the French Académie des Sciences
The webcast call will be held on Monday 28 February, 2022 from 6pm to 7.30pm CET (12pm to 1.30pm ET).
The presentation will be followed by a Q&A session with the management of AB Science.
Dial-In & Webcast Information
Webcast date: Monday, February 28, 2022. US: 12pm-1.30pm ET; Europe: 6pm-7.30pm CET
Number for the US: +1 646 722 4916
Number for Canada: +1 416 216 4194
Number for France: +33 1 70 71 01 59
International numbers (outside US, Canada and France): Numbers for other countries are listed on the webcast page
Conference ID: 89410827#
Webcast access link (access to the presentation) here
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).
Further information is available on AB Science’s website:
www.ab-science.com.
Forward-looking Statements - AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.
These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.
For additional information, please contact:
AB Science
Financial Communication & Media Relations
investors@ab-science.com
Media Relations – USA
RooneyPartners
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
Media Relations – France
NewCap
Arthur Rouillé
arouille@newcap.fr
+33 (0)1 44 71 00 15
Attachment
